Did you know? Nearly 10% of new cancer cases diagnosed each year in the U.S. are hematologic malignancies, including leukemia, lymphoma and myeloma. #AML remains a serious blood cancer with significant unmet need, underscoring the importance of continued innovation. $SNTI

At Senti, our mission is to create a new generation of smarter medicines designed to outsmart complex diseases. Through innovative Gene Circuit technology, we are advancing novel approaches with the potential to transform patient care. $SNTI #AML #Leukemia #Oncology

#DidYouSee - BioTuesdays featured our CEO, Timothy Lu! He discusses how the Company's Gene Circuit platform is advancing next-generation cell and gene therapies. Read More: bit.ly/4f7zCjo $SNTI #CellandGeneTherapy #Cancer

#StayInTheLoop Get the latest updates from Senti Bio delivered straight to your inbox. Sign up today: bit.ly/3ZVnb39 $SNTI #AML #Leukemia #Oncology

At Senti Bio, we are advancing intelligent Gene Circuits designed for next-generation cell and gene therapies with a focus on oncology. Guided by our values: Be Bold, Better Together, Build to Last. We are working to tackle hard-to-treat diseases. $SNTI #Leukemia #AML #Oncology

AML is the most common type of acute leukemia in adults, accounting for 80% to 85% of cases, with a 5-year survival rate of 31.7% in the United States at diagnosis. $SNTI #AML #Leukemia #Oncology

Don’t miss the latest from Senti Biosciences! Subscribe to email alerts for updates on our pipeline, research, and company news: bit.ly/3ZVnb39 $SNTI #Oncology #Leukemia

Our CEO, Tim Lu, highlighted a transformational milestone as positive FDA RMAT feedback advances SENTI-202 toward a potential registrational study in relapsed/refractory AML. Read more here: bit.ly/4wv4mCD $SNTI #AML #Oncology #CellTherapy

Our Chief Medical Officer, Kanya Rajangam, highlighted strong momentum for SENTI-202, supported by encouraging clinical activity, a favorable safety profile, and advancements in donor selection. Learn more: bit.ly/4wv4mCD $SNTI

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program bit.ly/4wv4mCD $SNTI

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase bit.ly/4dpqGFi $SNTI #CellTherapy #Oncology #AML